Vertaling van "study id relative " (Nederlands → Frans) :

TERMINOLOGIE

afwijkend(e) | elektrocardiogram [ECG] | afwijkend(e) | elektrofysiologische intracardiale-studies | afwijkend(e) | fonocardiogram | afwijkend(e) | vectorcardiogram
Anomalies (de):électrocardiogramme [ECG] | épreuves électrophysiologiques intracardiaques | phonocardiogramme | vectocardiogramme

IN-CONTEXT TRANSLATIONS

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.

Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)
Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)

Ontwikkelen van gemeenschappelijke methodologiën om de sleutelelementen van de gegevens inzake relative effectiveness te beoordelen, erkennen van deze beoordeling tussen de lidstaten en ook het prioritair herzien van de regelgeving inzake klinische studies.
Le développement de méthodologies communes pour évaluer les éléments clés des données en matière de relative effectiveness, la reconnaissance de cette évaluation entre les États membres et également la révision prioritaire de cette réglementation en matière d’études cliniques.

Dierckx, K. Casier, E. De Baere, L. De Ridder, C. De Sadeleer, H. De Winter, M. Lippens, S. Van Imschoot, D. Wulfrank, M. Simons. Real-life radiation burden to relatives of patients treated with iodine-131: a study in eight centres in Flanders (Belgium).
Real-life radiation burden to relatives of patients treated with iodine-131: a study in eight centres in Flanders (Belgium).

The purpose of this study was to quantify foot placement patterns relative to body post-stroke and investigate its relati [ publicatie ] [ 1/03/2012 ]
The purpose of this study was to quantify foot placement patterns relative to body post-stroke and investigate its relati [ publication ] [ 1/03/2012 ]

Results from the Japanese KYOTO HEART study, presented in September at the European Society of Cardiology Congress, demonstrated that the addition of Diovan to a non-ARB-based treatment regimen for high blood pressure provided a significant 45% relative risk reduction in cardiovascular events, including stroke, over a conventional non-ARB treatment regimen.
Les résultats de l’étude japonaise KYOTO HEART, présentés au Congrès de la Société Européenne de Cardiologie, ont prouvé que l’adjonction de Diovan lors d’un traitement contre l’hypertension non basé sur les ARA a conduit à une réduction importante de 45% du risque relatif d’accidents cardiovasculaires, notamment cérébraux, par rapport à un traitement non ARA conventionnel.